Publications by authors named "J O Schorge"
Article Synopsis
- - The NCCN Guidelines outline a comprehensive approach to diagnosing, staging, and treating ovarian, fallopian tube, and primary peritoneal cancers.
- - Recent developments in the use of PARP inhibitors, both as maintenance therapy and standalone treatments, have significantly influenced the recommendations in these guidelines.
- - These insights highlight the collaborative effort among experts to continuously update treatment protocols based on the latest research in ovarian cancer therapies.
Article Synopsis
- The study aimed to compare the effectiveness and side effects of two chemotherapy regimens, paclitaxel and carboplatin (PC), against bleomycin, etoposide, and cisplatin (BEP) in treating newly diagnosed or recurrent ovarian sex cord-stromal tumors (SCST).
- In a phase II trial involving 63 patients, the analysis showed that PC did not meet the criteria for being as effective as BEP, with a median progression-free survival of 27.7 months for PC compared to 19.7 months for BEP.
- Although PC had fewer serious adverse events (77% vs. 90%), the study concluded that it failed to demonstrate non-inferiority to BE
Article Synopsis
- Vulvar cancer is diagnosed in about 6,470 individuals each year, primarily as squamous cell carcinomas, constituting 5% to 8% of gynecologic cancers.
- Key risk factors include older age, HPV infection, smoking, inflammatory vulvar conditions, and weakened immune systems.
- The text reviews NCCN Clinical Practice Guidelines for treatments, surveillance, systemic therapies, and survivorship for those affected by vulvar cancer.
The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment. The guidelines also include details on histopathologic classification of cervical cancer regarding diagnostic features, molecular profiles, and clinical outcomes. The treatment landscape of advanced cervical cancer is evolving constantly.
View Article and Find Full Text PDFObjective: Assess outcomes of interval debulking surgery (IDS) after neoadjuvant chemotherapy via minimally invasive surgery (MIS) compared with laparotomy in patients with advanced epithelial ovarian cancer.
Methods: Patients diagnosed with stage IIIC or IV epithelial ovarian cancer between 2013 and 2018 who received neoadjuvant chemotherapy and IDS were identified in the National Cancer Database. Primary outcome was overall survival.